About Visum Pharma
Visum Pharma is a Healthcare company based in Haikou (China) founded in 2010. CDMO based out of China. Its focus areas include Biopharma Outsourcing, CDMO, Small Molecules & Peptides and Formulation.
Company details
Visum Pharma offers formulation development, contract manufacturing and analytical services. The company offers analytical services such as physical and chemical testing and batch release testing, including the development and validation of the content of various pharmaceutical dosage forms, the uniformity of related substances and methods of analysis. The company had received an oral solid tablets drug production license in 2012, the China New GMP Certification in 2013 and US FDA certification in 2016. Since its inception, the company has been engaged in the development of more than 40 products, including hypoglycemic drugs, blood pressure lowering drugs, antidepressants, anti-epileptic drugs. The companys development services cater to controlled release formulations, targeted drug delivery systems, extrusion - spheronization pellets, insoluble drug formulation design (hot melt extrusion method, amorphous recipe), and a variety of drug delivery systems (sublingual tablets, oral transmucosal administration and transdermal administration).
- Headquarters Haikou, China
- SectorsHealthcare
- Website visumpharma.com
- InvestorsZhejiang Hisoar Pharmaceutical
& 1 more
Funding Insights of Visum Pharma
- Total Rounds 1
- Investors Count 2
All 1 funding rounds of Visum Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2022 | Series B | – | Zhejiang Hisoar Pharmaceutical, Tianjin Haida Venture Capital Management | – |
2 investors in total: 2 institutional.
Investors in Visum Pharma
Visum Pharma has secured backing from 2 investors, including institutional and venture fund investors. Prominent investors backing the company include Zhejiang Hisoar Pharmaceutical and Haida Venture Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital investments are managed by this company. | hideavc.com | Tianjin, China | ||
Speciality raw materials, fine chemicals, and dye intermediates are manufactured. | 1966 | hisoar.com | Taizhou, China |
Investor details for Visum Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Visum Pharma
2 dated milestones of Visum Pharma across 12 years, from founding to its latest funding, stage changes and deals.
- Founded Visum Pharma is founded.
- Funding First funding round.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Visum Pharma
Complete news archive for Visum Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Visum Pharma
Visum Pharma was founded in 2010 and raised its 1st funding round 12 years after it was founded.
Visum Pharma is headquartered in Haikou, China. It is registered at Haikou, Hainan, China.
Visum Pharma offers formulation development, contract manufacturing and analytical services. The company offers analytical services such as physical and chemical testing and batch release testing, including the development and validation of the content of various pharmaceutical dosage forms, the uniformity of related substances and methods of analysis. The company had received an oral solid tablets drug production license in 2012, the China New GMP Certification in 2013 and US FDA certification in 2016. Since its inception, the company has been engaged in the development of more than 40 products, including hypoglycemic drugs, blood pressure lowering drugs, antidepressants, anti-epileptic drugs. The companys development services cater to controlled release formulations, targeted drug delivery systems, extrusion - spheronization pellets, insoluble drug formulation design (hot melt extrusion method, amorphous recipe), and a variety of drug delivery systems (sublingual tablets, oral transmucosal administration and transdermal administration).
Visum Pharma has 2 investors. Key investors include Zhejiang Hisoar Pharmaceutical, and Haida Venture Capital.